← Back to Clinical Trials
Recruiting NCT05731414

NCT05731414 Outcomes From Remediation and Behavioural Intervention Techniques

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05731414
Status Recruiting
Phase
Sponsor University of Toronto
Condition Schizophrenia
Study Type INTERVENTIONAL
Enrollment 360 participants
Start Date 2023-03-01
Primary Completion 2027-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Cognitive Behavioural Therapy for Psychosis (CBTp)Cognitive Remediation Therapy (CR)Befriending

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 360 participants in total. It began in 2023-03-01 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

It is currently unknown what factors predict response to Cognitive Behavioural Therapy for Psychosis (CBTp) or Cognitive Remediation Therapy (CR) among individuals with schizophrenia-spectrum disorders, thus the current trial will examine predictors of response to determine who requires the combined intervention and who might respond sufficiently to either monotherapy.

Eligibility Criteria

Inclusion Criteria: * Aged 18-65 years * Diagnosed with schizophrenia-spectrum disorders * Can read, write, and speak English Exclusion Criteria: * Neurodevelopmental disability or neurocognitive disorder * CBT or CR in the past 6 months

Contact & Investigator

Central Contact

Hanna Hamzai, HBSc

✉ hanna.hamzai@mail.utoronto.ca

📞 6476896098

Principal Investigator

Michael W Best, PhD, C.Psych

PRINCIPAL INVESTIGATOR

University of Toronto Scarborough

Frequently Asked Questions

Who can join the NCT05731414 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05731414 currently recruiting?

Yes, NCT05731414 is actively recruiting participants. Contact the research team at hanna.hamzai@mail.utoronto.ca for enrollment information.

Where is the NCT05731414 trial being conducted?

This trial is being conducted at Scarborough Village, Canada, Whitby, Canada.

Who is sponsoring the NCT05731414 clinical trial?

NCT05731414 is sponsored by University of Toronto. The principal investigator is Michael W Best, PhD, C.Psych at University of Toronto Scarborough. The trial plans to enroll 360 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology